AVITA Medical, Inc.
Close on Oct 19, 2026
- Market cap
- $404.05M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | $21.70M | $-0.25 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | During market hours | $19.30M | $-0.35 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | During market hours | $17.60M | $-0.38 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $17.10M | $-0.46 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | $18.40M | $-0.38 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | During market hours | $18.50M | $-0.53 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 13, 2025 | During market hours | $18.40M | $-0.44 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | $19.50M | $-0.62 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| year-over-year growth | full-year 2026 | 20% to 24% growth | Raised |
| revenue | full-year 2026 | $86.00M to $89.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements AVITA Medical filed with the SEC
AVITA Medical Reports Second Quarter Results,
Results of operations · EX-99.1 to Form 8-K
AVITA Medical Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
AVITA Medical Names Cary Vance as Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook
Material agreement · Agreement terminated · Results of operations · New financial obligation · Unregistered share sale · EX-99.1 to Form 8-K
AVITA® Medical Reports Third Quarter 2025 Financial Results
Material agreement · Results of operations · EX-99.1 to Form 8-K
AVITA Medical Announces CEO Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AVITA Medical Successfully Completes Australian Equity Raise
Other events · EX-99.1 to Form 8-K
AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation
Material agreement · Results of operations · EX-99.1 to Form 8-K
AVITA Medical Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results
Material agreement · Results of operations · EX-99.1 to Form 8-K
AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
AVITA Medical Reports Third Quarter Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
AVITA Medical Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
AVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound Care
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AVITA Medical Announces FDA Approval of RECELL GO
Other events · EX-99.1 to Form 8-K
AVITA Medical Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
AVITA Medical Updates Expected First Quarter 2024 Revenue
Results of operations · EX-99.1 to Form 8-K
AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific
Material agreement · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year
Results of operations · EX-99.1 to Form 8-K
AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
AVITA Medical Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
AVITA Medical Announces Appointment of David O’Toole as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance
Results of operations · Executive or director change · EX-99.1 to Form 8-K
FQ1 2023 Earnings Call Transcripts
Results of operations · Executive or director change · EX-99.2 to Form 8-K
AVITA Medical to Announce First Quarter 2023 Financial Results
Other events · EX-99.1 to Form 8-K
AVITA Medical Appoints New Non-Executive Member to the Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Accelerating Our Growth Profile Q4 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
AVITA Medical to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide 2023 Financial
Other events · EX-99.1 to Form 8-K
AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo
Other events · EX-99.1 to Form 8-K
Annual Meeting of Stockholders DECEMBER
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders
Shareholder vote results · Regulation FD disclosure · EX-99.2 to Form 8-K
AVITA Medical Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL ® System
Other events · EX-99.1 to Form 8-K